Syntec Optics (OPTX) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
31 Mar, 2026Executive summary
Net sales for 2025 were $28.1 million, down 1.3% from 2024, with gross profit rising 15% to $6.5 million due to lower costs of goods sold despite a slight sales decline.
Net loss improved to $1.8 million in 2025 from $2.5 million in 2024, driven by reduced general and administrative expenses and cost controls.
The company focuses on vertically integrated manufacturing for optics and photonics, serving defense, medical, consumer, and communications markets.
Three customers accounted for 48% of 2025 revenues, highlighting customer concentration risk.
Financial highlights
Gross margin increased to 23% in 2025 from 20% in 2024.
General and administrative expenses decreased by 15% to $7.0 million in 2025.
Adjusted EBITDA for 2025 was $3.0 million, up from $2.2 million in 2024, reflecting improved operational efficiency and exclusion of non-recurring items.
Cash provided by operating activities was $0.7 million in 2025, compared to cash used of $0.9 million in 2024.
As of December 31, 2025, $6.8 million was outstanding under the revolving credit facility, with $0.7 million available.
Outlook and guidance
Management expects to remain in compliance with credit facility covenants and believes liquidity is sufficient for at least the next twelve months.
Growth strategy includes expanding product offerings, entering new end-markets, and pursuing inorganic growth through acquisitions.
The company anticipates improved profitability in future periods, supported by operational efficiency and strong customer demand.
Latest events from Syntec Optics
- Strong H1 2025 profit growth and margin expansion driven by defense, biomedical, and communications.OPTX
Q2 202513 Feb 2026 - Gross margin rose to 29% in H1 2025 as sales and adjusted EBITDA improved year-over-year.OPTX
Q4 202413 Feb 2026 - Q1 2025 net income turned positive on 13% sales growth and improved margins.OPTX
Q1 202513 Feb 2026 - Q3 2025 revenue rose sequentially but margins fell; liquidity improved and Q4 outlook is positive.OPTX
Q3 202512 Feb 2026 - Q2 sales up 12% sequentially, product growth strong, and Q3 outlook robust.OPTX
Q2 20242 Feb 2026 - Q3 sales up 19% year-over-year, but higher costs led to a net loss; Q4 outlook is positive.OPTX
Q3 202413 Jan 2026 - Virtual meeting to vote on directors, auditor, RSUs, and governance amendments; board recommends approval.OPTX
Proxy Filing8 Dec 2025 - Shareholders will vote on director elections, auditor ratification, and RSU grants at the virtual annual meeting.OPTX
Proxy Filing2 Dec 2025 - Shareholders will vote on directors, auditor ratification, RSU grants, and governance amendments.OPTX
Proxy Filing29 Nov 2025